282 Spam-Free Article(s) Found
Symbol Name Last Close Mkt Cap DailyStocks'
Our DailyStocks’ Rating System is a proprietary algorithm that combines the vote of the investor community and legendary trader Richard Dennis’ Turtle Trader System and the System Rules of the Turtle Traders Each day, we generate Buy, Sell, Uptrend or Downtrend signals for 3000 Stocks in the U.S. Markets.
Vote Now!
Wednesday’s Close
INCY Incyte Corporation $67.04 $14.25B N/A
Article Searches
Will Incyte (INCY) Gain on Rising Earnings Estimates? http://www.zacks.com/stock/news/604570/will-incyte-incy-gain-on-rising-earnings-estimates?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_8-604570 Nov 05, 2019 - Incyte (INCY) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.
Incyte Corporation's (INCY) CEO Hervé Hoppenot on Q3 2019 Results - Earnings Call Transcript https://seekingalpha.com/article/4300014-incyte-corporations-incy-ceo-herve-hoppenot-q3-2019-results-earnings-call-transcript?source=feed_sector_healthcare Oct 29, 2019 - Incyte Corporation's (NASDAQ:INCY) Q3 2019 Results Earnings Conference Call October 29, 2019, 08:00 AM ET Company Participants Michael Booth - Divisional Vice President of Investor Relations and Corpo
Incyte Corp (INCY) Q3 2019 Earnings Call Transcript https://www.fool.com/earnings/call-transcripts/2019/10/29/incyte-corp-incy-q3-2019-earnings-call-transcript.aspx?source=iedfolrf0000001 Oct 29, 2019 - INCY earnings call for the period ending September 30, 2019.
Incyte (INCY) Beats on Q3 Earnings & Sales, Ups Jakafi View http://www.zacks.com/stock/news/590995/incyte-incy-beats-on-q3-earnings-sales-ups-jakafi-view?cid=CS-ZC-FT-analyst_blog|earnings_article-590995 Oct 29, 2019 - Incyte (INCY) reports better-than-expected results for the third quarter of 2019, owing to strong Jakafi sales.
Drug/Biotech Stock Q3 Earnings Due on Oct 29: MRK, PFE & More http://www.zacks.com/stock/news/588895/drug-biotech-stock-q3-earnings-due-on-oct-29-mrk-pfe-more?cid=CS-ZC-FT-analyst_blog:_earnings_preview_-_esp|earnings_preview_-_esp-588895 Oct 28, 2019 - Four drug/biotech stocks are scheduled to release third-quarter results on Oct 29. Let's see how these companies are placed before their earnings call.
Sanofi (SNY) to Report Q3 Earnings: What's in the Cards? http://www.zacks.com/stock/news/588721/sanofi-sny-to-report-q3-earnings-whats-in-the-cards?cid=CS-ZC-FT-analyst_blog|earnings_preview-588721 Oct 28, 2019 - Sanofi's (SNY) Specialty Care and Vaccines units are likely to have driven third- quarter earnings.
What's in the Cards for AbbVie (ABBV) This Earnings Season? http://www.zacks.com/stock/news/584231/whats-in-the-cards-for-abbvie-abbv-this-earnings-season?cid=CS-ZC-FT-analyst_blog|earnings_preview-584231 Oct 25, 2019 - AbbVie's (ABBV) Q3 sales may have been weighed down by biosimilar competition for Humira in international markets. However, strong growth of oncology drugs might have offset impact of Humira's international sales erosion.
Will Nuplazid Aid Growth for ACADIA (ACAD) in Q3 Earnings? http://www.zacks.com/stock/news/584443/will-nuplazid-aid-growth-for-acadia-acad-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-584443 Oct 25, 2019 - During ACADIA's (ACAD) third-quarter 2019 conference call, investor focus will be on the sales figure of its only marketed drug Nuplazid and its label expansion studies.
Can CF Drugs Drive Growth for Vertex (VRTX) in Q3 Earnings? http://www.zacks.com/stock/news/584435/can-cf-drugs-drive-growth-for-vertex-vrtx-in-q3-earnings?cid=CS-ZC-FT-analyst_blog|earnings_preview-584435 Oct 25, 2019 - During Vertex's (VRTX) third-quarter earnings call, investor focus will be on the uptake of its newest CF drug Symdeko and the update on the recent approval of Trikafta triple combination regimen.
BioMarin's (BMRN) Earnings & Revenues Beat Estimates in Q3 http://www.zacks.com/stock/news/582538/biomarins-bmrn-earnings-revenues-beat-estimates-in-q3?cid=CS-ZC-FT-analyst_blog|earnings_article-582538 Oct 24, 2019 - BioMarin (BMRN) rides high on earnings and revenue beat in the third quarter of 2019.

Pages: 123456...29

Page 1>